Oliver Dolan - 11 Sep 2026 Form 4 Insider Report for Korro Bio, Inc. (KRRO)

Reporting relationship: Senior Vice President, Finance
Issuer ticker: KRRO
Reported as of: 11 Sep 2026
Net transaction value: -$68.58
SEC form: 4
Accepted by SEC: 14 Sep 2026, 16:05:25 UTC
Prior SEC filing: 10 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Cerio, Attorney-in-fact

Key filing fact

Oliver Dolan filed Form 4 for Korro Bio, Inc. (KRRO) on 14 Sep 2026.

Key facts

This page summarizes Oliver Dolan's Form 4 filing for Korro Bio, Inc. (KRRO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Sep 2026, 16:05.

Change

Previous filing in this sequence was filed on 10 Sep 2026.
Current net transaction value: -$68.58.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002053835 Primary reporting owner

Dolan Oliver

Relationship: Senior Vice President, Finance
Address: C/O KORRO BIO, INC., 60 FIRST STREET, 2ND FLOOR, SUITE 250, CAMBRIDGE
Signature: /s/ Jeffrey Cerio, Attorney-in-fact
Signature date: 14 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KRRO transaction

Common Stock

Sale

Transaction value: $68.58
Shares: -5
Change %: -0.03%
Price: $13.72
Shares after: 16,241
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026.

Footnote F2

The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.51 to $13.85, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.

Footnote F3

Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.